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Abstract Several herbal medicines improve hyperlipidemia,
diabetes and cardiovascular diseases. However, the molecular
mechanism underlying this improvement has not yet been
clarified. In this study, we found that several isoprenols, common
components of herbal plants, activate human peroxisome
proliferator-activated receptors (PPARs) as determined using
the novel GAL4 ligand-binding domain chimera assay system
with coactivator coexpression. Farnesol and geranylgeraniol that
are typical isoprenols in herbs and fruits activated not only
PPARQ but also PPARK as determined using the chimera assay
system. These compounds also activated full-length human
PPARQ and PPARK in CV1 cells. Moreover, these isoprenols
upregulated the expression of some lipid metabolic target genes
of PPARQ and PPARK in 3T3-L1 adipocytes and HepG2
hepatocytes, respectively. These results suggest that herbal
medicines containing isoprenols with dual action on both PPARQ
and PPARK can be of interest for the amelioration of lipid
metabolic disorders associated with diabetes. ß 2002 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
It is known that several herbal medicines improve diabetes
mellitus, hyperlipidemia, and cardiovascular diseases associ-
ated with an abnormality in lipid metabolism [1,2]. Such
plants contain many bioactive phytochemicals. In particular,
terpenoids, which include carotenoids, isoprenoids and their
alcohols (isoprenols), are contained in many plants not only
for herbal use but also for dietary use [3]. It is known that
these dietary terpenoids have multifunctions, such as the sup-
pression of tumor proliferation [3^5], induction of apoptosis
[6] and regulation of cation channels [7]. Some terpenoids of
intermediates of cholesterol synthesis regulate the activity of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase, a key enzyme in cholesterol synthesis, by controlling the
degradation of the enzyme [8,9]. Such functions of dietary
terpenoids are signi¢cant for the therapy of diseases, such as
cancers or cardiovascular diseases, using food factors.
Peroxisome proliferator-activated receptors (PPARs) are li-
gand-activated transcription factors of a nuclear receptor
superfamily [10]. PPARs have three subtypes of K, N and Q.
PPARN is ubiquitously expressed [11] and is thought to be
involved in cell proliferation or carcinogenesis [12,13]. PPARQ
is an essential transcription factor in adipogenesis [14] and the
overexpression of PPARQ enhances adipogenesis in vitro [15].
On the other hand, hetero-PPARQ knockout results in the
inhibition of adipogenesis in vivo, although null-PPARQ de¢-
cient mice are embryo lethal [16^18]. Moreover, PPARQ is a
regulator of the insulin resistance in adipose tissues. Thiazo-
lidinediones, which are anti-diabetic drugs, improve insulin
resistance and this e¡ect depends on the promotion of adipo-
cyte di¡erentiation via PPARQ activation in adipocytes. It
appears that the improvement of insulin resistance by PPARQ
activation is due to the increase in the number of di¡erentiat-
ing adipocytes with a high ability to uptake and to utilize
glucose [19,20]. PPARK is highly expressed in the liver, skel-
etal muscle and kidney [11]. PPARK regulates the expression
of target genes involved in lipid catabolism [21] and plays a
role in the clearance of circulating and cellular lipids as the
target of ¢brates, which are anti-hyperlipidemic drugs [22].
The reduction in the level of circulating or cellular lipids by
PPARK activation is attributed to the stimulation of fat deg-
radation in peripheral tissues expressing PPARK [23]. Re-
cently, it is thought that a dual or cross activation of both
PPARK in the liver and PPARQ in adipocytes is important for
the improvement of hyperlipidemia and diabetes associated
with obesity.
Here, we report a novel function of terpenoids, particularly
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isoprenols used in herbal medicines. First, we developed a
highly sensitive screening system for PPAR ligands with coex-
pression of coactivator cAMP-response-element-binding pro-
tein (CREB)-binding proteins (CBP). Next, we elucidated that
isoprenols (also called terpenols or polyprenyl alcohols), such
as farnesol, geranylgeraniol and geraniol activated both PPARQ
and PPARK as determined using our highly sensitive screen-
ing system. The isoprenol is a type of terpenoids, which are
contained in herbal medicines and dietary food. These alco-
hols regulated the transcription of PPAR target genes in 3T3-
L1 adipocytes and HepG2 hepatocytes. These ¢ndings show
the molecular mechanism of the e¡ects of herbal plants and
the possibility to control the clearance of circulating and cel-
lular lipids using food factors.
2. Materials and methods
2.1. Chemical reagents
All carotenoids, terpenoids and feno¢brate were from Nakalai Tes-
que (Kyoto, Japan) or Sigma (MO, USA). Thiazolidinedione T174, a
speci¢c ligand for PPARQ [24], was kindly provided by Tanabe Seiya-
ku (Osaka, Japan). These compounds were diluted with dimethyl sulf-
oxide (DMSO) to prepare the stock solutions (10^100 mM). All other
chemicals were of guaranteed reagent grade or tissue culture grade.
2.2. Reporter plasmids and luciferase assays
To generate a fusion protein expression vector (pM-PPARQ and
pM-PPARK) containing residues 1^147 of the GAL4 DNA-binding
domain (DBD) and 204^505 of the human PPARQ ligand-binding
domain (LBD) or 167^467 of the human PPARK LBD, the LBDs
of hPPARQ and hPPARK from human adipose tissue or liver
cDNA libraries (Clontech, CA, USA) were ampli¢ed by polymerase
chain reaction (PCR) and subcloned into the pM mammalian expres-
sion plasmid (Clontech). The reporter plasmid (p4xUASg-tk-luc) con-
tains four copies of a 17-mer upstream activating sequence (UAS) for
GAL4 DBD and a thymidine kinase gene promoter (tk-promoter) in
front of luciferase cDNA. p4xPPRE-tk-luc contains four copies of the
PPAR-response element followed by a tk-promoter and a luciferase
reporter gene. pRL-CMV (Promega, WI, USA) was used as an inter-
nal control for normalizing transfection e⁄ciency. pCMX-CBP (a
CBP expression vector) and pSK-CBP (a control plasmid not express-
ing CBP proteins) were kindly provided by Dr. Goodman.
CV1 monkey kidney cells were from the American Type Culture
Collection (ATCC). CV1 cells were grown in maintenance medium
(Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
bovine serum, and 10 mg/ml penicillin and streptomycin) at 37‡C in
5% CO2. In the case of the GAL4 chimera system, pM-hPPARQ or
pM-PPARK (0.2 Wg/well), p4xUASg-tk-luc (0.2 Wg/well), pRL-CMV
(0.2 ng/well) and pCMX-CBP or pSK-CBP (0.2 Wg/well) were trans-
fected into CV1 cells cultured on 24-well tissue culture plates. In the
case of a full-length PPAR system, p4xPPRE-tk-luc (0.2 Wg/well) and
pDEST-hPPARQ or pDEST-hPPARK (full-length PPAR expression
vectors) (0.2 Wg/well) were also transfected into CV1 cells cultured
on 24-well tissue culture plates. In both cases, transfection was per-
formed with a LipofectAMINE system (Invitrogen, CA, USA). After
transfection, the cells were cultured for 24 h, and compounds for
ligand assay were added into the medium at appropriate concentra-
tions. After an additional 24-h incubation, the cells were lysed for
luciferase assay performed using a Dual-Luciferase Reporter Gene
Assay system (Promega) according to the manufacturer’s protocol.
2.3. Adipocyte and hepatocyte cultures
Di¡erentiation assays on adipocytes were performed using materials
and reagents as previously described [25]. In brief, 3T3-L1 murine
preadipocytes (from ATCC) were maintained in the maintenance me-
dium with 200 WM ascorbic at 37‡C in 5% CO2. After 4 days when
con£uence was reached, the cells were incubated in the di¡erentiation
medium (DM) containing 0.25 WM dexamethazone, 10 Wg/ml insulin,
and 0.5 mM 1-methyl-3-isobutylxanthine as in the maintenance me-
dium. After 40 h, the cell culture medium was changed to post-DM
containing 5 Wg/ml insulin as in the maintenance medium, and fresh
post-DM was refed every 2 days. 7 days after di¡erentiation induc-
tion, the cells were washed with phosphate-bu¡ered saline and total
RNA was prepared using a RNeasy Mini Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol.
HepG2, a human hepatocarcinoma cell line (from ATCC), was
maintained on six-well tissue culture plates containing the mainte-
nance medium at 37‡C in 5% CO2. At 80% con£uent, 1 Wg/well of
a human PPARK expression vector, pDEST-hPPARK, or control
vector was transfected into cells using a LipofectAMINE Plus system
(Invitrogen) and the cells were then cultured in the maintenance me-
dium for 24 h. The transfected cells were incubated in an assay me-
dium containing isoprenols as samples or feno¢brate as a positive
control for PPARK activation. After 48 h, total RNA was isolated
as described above.
2.4. RNA preparations and real-time £uorescence monitoring reverse
transcription (RT)-PCR
Using M-MLV Reverse Transcriptase (Invitrogen), the total RNA
was reverse-transcribed according to the manufacturer’s instructions
with a thermal cycler (Takara PCR Thermal Cycler SP: Takara Shuzo
Co., Shiga, Japan). To quantify mRNA expressions, PCR was per-
formed using a £uorescence temperature cycler (LightCycler System:
Roche Diagnostics, Mannheim, Germany). The oligonucleotide prim-
ers of mouse or human PPAR target genes were designed using a
PCR primer selection program at the website of the Virtual Genomic
Center from the GenBank database as follows: mouse lipoprotein
lipase (LPL), adipocyte fatty acid-binding protein (aP2), human liver
carnitine palmitoyltransferase 1 (CPT1A), acyl-CoA synthetase
(ACS), enoyl-CoA hydratase (ECH), and mouse/human glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (Table 1). Ampli¢cation
was performed according to a published protocol [26]. Brie£y, the
reaction solution (10 Wl ¢nal volume) contained 3 WM MgCl2, 2.0 Wl
of LightCycler DNA Master SYBR Green I dye, and 5 WM of each
primer. The standard ampli¢cation program included 30 cycles of
three steps each, which involved heating the product to 95‡C at
20‡C/s with a 30 s hold, annealing to 55‡C at 20‡C/s with a 5 s
Table 1
Sequences of PCR primers and GenBank accession numbers
Strain Gene Forward (F), Reverse (R) GenBank accession number
Mouse GAPDH F: GAAGGTCGGTGTGAACGGATT M32599
R: GAAGACACCAGTAGACTCCACGACATA
aP2 F: AAAGACAGCTCCTCCTCGAAGGTT K02109
R: TGACCAAATCCCCATTTACGC
LPL F: ATCCATGGATGGACGGTAACG J03302
R: CTGGATCCCAATACTTCGACCA
Human GAPDH F: TCATCCATGACAACTTTGGTATCG M33197
R: GAGCTTGACAAAGTGGTCGTTGA
CPT1A F: AATCATCAAGAAATGTCGCACGA NM001876
R: AGGCAGAAGAGGTGACGATCG
ACS F: AGCAGAGCTTCGCAGCGGC L09229
R: CTGCTGTTTTCGCTGGGTCC
ECH F: TCTGCAGGTGCTGATATTCGTG NM001966
R: AATTGGCTTGTTGCAGAGTCTACG
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hold, and extension to 72‡C at 20‡C/s with a 10 s hold. The £uores-
cence at 530 nm was recorded on line at the end of the extension
phase. Standards of PCR products ampli¢ed from the mRNA of
adipocytes or hepatocytes were prepared by the same method as de-
scribed above using the LightCycler. Each PCR product was sub-
cloned into T-easy vectors (Promega) and used as standard plasmids
for standard templates. The copy number of each standard plasmid
was calculated from the absorbance at 260 nm and the molecular
weight of each plasmid. The copy numbers of standards and samples
were ampli¢ed simultaneously in the LightCycler. The ¢rst cycle num-
ber indicated speci¢c £uorescence against noise, and the logarithm of
the concentration of the PCR product standard, the external standard
curve, was calculated with the LightCycler software version 3. To
con¢rm the ampli¢cation of speci¢c transcripts, melting curve pro¢les
were produced at the end of each run.
2.5. Statistical analysis
The data are presented as means þ S.E.M. and were statistically
analyzed using the unpaired t-test or the Welch t-test when variances
were heterogeneous. Di¡erences were considered signi¢cant when P
was 6 0.05.
3. Results
3.1. Cotransfection of coactivator CBP improves the sensitivity
of PPARQ ligand assay
To study the e¡ects of a coactivator in luciferase assays, we
performed PPARQ ligand assays using the GAL4 chimera sys-
tem with or without the coexpression of CBP, a major coac-
tivator of nuclear receptors including PPARs. Cotransfection
of 0.4 Wg of pCMX-CBP, a CBP expression vector, induced a
higher level of PPARQ/GAL4 transactivation than that of
pSK-CBP, a CBP cloning vector (does not express the CBP
protein) as shown in Fig. 1A. CBP coexpression induced
about 1.8-fold activation at 10 WM T174 thiazolidinedione.
Under the same conditions, luciferase activity was stimulated
by adding oleic acid. Oleic acid is a ligand of PPARQ as well
as polyunsaturated fatty acids [27] and a major component of
dietary fatty acids. The concentration of total fatty acids in
human serum is 200^500 WM [28]. Thus, oleic acid is a sig-
ni¢cant food-derived ligand of PPARQ at a physiologically
enough concentration to bind to PPARQ. In our luciferase
assays, oleic acid activated PPARQ in a dose-dependent man-
ner (Fig. 1B). The activation of PPARQ by addition of oleic
acid was enhanced by CBP coexpression as well as that of
TZD (1.6-fold at 100 WM). This result suggests the possibility
that CBP coexpression can improve the sensitivity of PPARQ/
GAL4 luciferase assays.
3.2. Several isoprenols stimulate the activity of PPARQ
We carried out the screening for novel PPAR ligands in
natural compounds present in herbal plants using novel lucif-
erase assays with CBP coexpression. As shown in Fig. 2A, we
used several terpenoids or carotenoids for this screening, be-
cause these compounds are present in many herbal plants [3].
Some terpenoids called isoprenols, such as geraniol, farnesol
and geranylgeraniol (their chemical structures are shown in
Fig. 2B), activated PPARQ/GAL4 chimera transactivations
at 100 WM. At this concentration, the activities induced by
geraniol, farnesol and geranylgeraniol were about 2.2-, 4.1-
and 3.7-fold as compared to vehicle control, respectively.
The isoprenols exerted their e¡ects in a dose-dependent man-
ner (Fig. 3A). The ED50s, the concentration showing a half
activity of the maximum in ligand-dependent activation, for
PPARQ activated by geraniol, farnesol and geranylgeraniol
Fig. 1. E¡ects of coactivator CBP coexpression determined by lucif-
erase ligand assays. CV1 cells were cotransfected with p4xUASg-tk-
luc (a reporter plasmid regulated by GAL4/PPARQ chimera protein),
pM-hPPARQ (a expression plasmid for GAL4/PPARQ chimera pro-
tein) and pCMX-CBP expression vectors (a expression plasmid for
CBP, closed circles) or pSK-CBP control plasmids (a control plas-
mid containing CBP cDNA, open circles) and pRL-CMV (an inter-
nal control not regulated by compound additions). The activity of a
vehicle control was set at 100% and the relative luciferase activities
were presented as fold induction to that of the vehicle control. All
values are represented as means þ S.E.M. of 3^4 tests. *P6 0.05 ver-
sus controls without CBP coexpression at the same concentrations
of each compound. A: Transfected CV1 cells were treated with
T174 thiazolidinedione at various concentrations for 24 h, and cell
extracts were subsequently assayed for luciferase activities as de-
scribed in Section 2. B: Transfected CV1 cells were treated with
oleic acid. Closed circles indicate CV1 cells transfected with pCMX-
CBP; open circles, CV1 cells transfected with pSK-CBP, a control
plasmid to make the amount of DNA transfected constant.
FEBS 25863 28-3-02
N. Takahashi et al./FEBS Letters 514 (2002) 315^322 317
were about 135, 28 and 60 WM, respectively. On the other
hand, squalene had no e¡ect on PPARQ transactivation
(Fig. 3A). These results indicate that some isoprenols induced
the transactivation of PPARQ.
Next, we tested whether isoprenols can induce PPARK
stimulation in our luciferase assay system. These PPARK li-
gand assays were performed with CBP coexpression because
this coexpression was found to improve the sensitivity of
PPARK ligand assays as well as PPARQ ligand assays
(data not shown). Although geraniol had no e¡ect, farnesol
and geranylgeraniol dose-dependently activated PPARK/
GAL4 chimera transactivation (at 100 WM, 10- and 8.6-fold
Fig. 2. E¡ects of various carotenoids and terpenoids on the activa-
tion of the PPARQ ligand and the chemical structures of isoprenols.
A: pM-hPPARQ, p4xUASg-tk-luc and pRL-CMV were transfected
into CV1 cells together with pCMX-CBP and, 24 h after the trans-
fection, the cells were treated with various terpenoids at 100 WM for
24 h. These compounds are classi¢ed into several groups: non-acylic
isoprenoids (austricine and leucomisine); carotenoids (xanthophylls,
zeaxanthin, L-cryptoxanthin, astaxanthin and L-carotene); long-
chain isoprenoids (lycopene and squalene); isoprenols (geranylgera-
niol, farnesol and geraniol); short-chain isoprenoids (isoprene, per-
illic acid and d-limonene). The activity of a vehicle control was set
at 100% and the relative luciferase activities were presented as fold
induction to that of the vehicle control. The values are mean-
s þ S.E.M. of 3^4 tests. *P6 0.05 compared with vehicle controls
(DMSO only). B: The chemical structures of isoprenols showing
PPAR activation; a, geraniol (GOH); b, farnesol (FOH); c, gera-
nylgeraniol (GGOH); d, squalene. Isoprenols have several isopre-
noid units in their structures and one hydroxyl group.
Fig. 3. Isoprenols activated PPARs as determined by luciferase li-
gand assays using the PPAR chimera system. p4xUASg-tk-luc,
pRL-CMV and pCMX-CBP were transfected into CV1 cells togeth-
er with pM-hPPARQ (A) or pM-hPPARK (B) and then, 24 h after
the transfection, the cells were treated with farnesol (FOH; closed
circles), geranylgeraniol (GGOH; open circles), geraniol (GOH;
closed squares), and squalene (open squares) at various concentra-
tions for 24 h. The activity of a vehicle control was set at 100%
and the relative luciferase activities were presented as fold induction
to that of the vehicle control. The values are means þ S.E.M. of 3^4
tests. *P6 0.05 compared with vehicle controls.
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increases compared with that of the vehicle control, respec-
tively) (Fig. 3B). These activities were almost the same as that
of 10 WM feno¢brate, one of the ¢brates (anti-hyperlipidemia
drugs) used as a positive control for PPARK (data not
shown) [29]. The ED50s for PPARK activation by farnesol
and geranylgeraniol were about 5.5 and 62 WM, respectively.
In this regard, these isoprenols have the e¡ects of dual or
cross activation of both PPARQ and PPARK.
3.3. Isoprenols activate full-length PPARQ and PPARK
It was investigated whether isoprenols activate full-length
PPARs using the p4xPPRE-tk-luciferase reporter plasmid.
T174 thiazolidinedione stimulated PPAR-response element
(PPRE)-dependent luciferase activities in human PPARQ-
transfected CV1 cells (about 8.3-fold at 10 WM) (data not
shown). Farnesol and geranylgeraniol also upregulated lucif-
erase activities in a dose-dependent manner (Fig. 4A). The
addition of 100 WM farnesol strongly induced luciferase activ-
ity 4.8-fold, although geranylgeraniol weakly induced lucifer-
ase activity 2.6-fold. Moreover, these isoprenols activated the
transcription of pPPRE luciferase in human PPARK-trans-
fected CV1 cells (Fig. 4B). Farnesol and geranylgeraniol in-
duced luciferase activities 5.1- and 2.8-fold, respectively, at
100 WM. On the other hand, the addition of geraniol only
very weakly induced luciferase activity at 100 WM in either
human PPARQ- or PPARK-transfected cells. These results
were consistent with those using the GAL4/PPAR chimera
system. Therefore, taken together, these results indicate that
isoprenols activate both full-length PPARQ and PPARK.
3.4. Isoprenols induce the expressions of PPAR target genes in
adipocytes and hepatocytes
We attempted to elucidate the e¡ects of isoprenols on cell
functions via PPAR activation. First, we used di¡erentiation-
induced 3T3-L1 cells as di¡erentiated adipocytes. 7 days after
di¡erentiation induction, 3T3-L1 cells di¡erentiated into adi-
pocytes with high glycerophosphate dehydrogenase activity,
a marker of adipocyte di¡erentiation, and high-level expres-
sion of PPARQ (data not shown) [30]. At this point, PPARQ
ligands can e⁄ciently induce PPARQ target genes in the cells.
T174 thiazolidinedione, farnesol, or geranylgeraniol was
added into the medium of the 3T3-L1 adipocytes and the
culture was incubated for 24 h. The addition of 10 WM
T174 thiazolidinedione resulted in 7.7- and 2.9-fold increase
in the expression levels of both aP2 and LPL, respectively,
under this condition. Although there was no increase in LPL
expression level, the addition of 50 WM farnesol and geranyl-
geraniol resulted in 6.0- and 5.2-fold increases in the expres-
sion level of aP2 in 3T3-L1 adipocytes compared with that of
the vehicle control (Fig. 5A). These data indicate that isopre-
nols regulate an endogenous promoter region of aP2 in 3T3-
L1 adipocytes.
Second, we used HepG2 human hepatocarcinoma cells to
investigate whether isoprenols can induce expressions of
PPARK target genes in hepatocytes. We transfected pDEST-
hPPARK (a human PPARK expression vector) into HepG2
cells and the transfected HepG2 cells were treated for
48 h with 20 WM feno¢brate as a positive control and with
isoprenols (100 WM) after 24 h after transfection. Transfection
e⁄ciencies of pDEST-hPPARK into HepG2 cells were not
di¡erent from each well in preliminary experiments (data
not shown). Among the target genes that were already
reported to be upregulated by PPARK in HepG2 cells [21], the
expression levels of CPT1A and ACS increased 6.2- and 4.8-
fold, respectively, following the addition of feno¢brate
compared with that of the vehicle control. The addition of
farnesol resulted in a 4.2-fold increase in the CPT1A expres-
sion level and a 6.0-fold increase in the ACS expression com-
pared with that of the vehicle control (Fig. 5B). The addition
of geranylgeraniol resulted in no di¡erence in the CPT1A
expression level but a 5.4-fold increase in the ACS expression
Fig. 4. Farnesol and geranylgeraniol e⁄ciently activated full-length
PPARs in cells. p4xPPRE-tk-luc was transfected into CV1 cells to-
gether with pDEST-hPPARQ (A) or pDEST-hPPARK (B). 24 h
after the transfection, the cells were treated for 24 h with isoprenols
at various concentrations; closed circles, farnesol (FOH); open
circles, geranylgeraniol (GGOH); closed squares, geraniol (GOH);
open squares, squalene. The activity of a vehicle control was set at
100% and the relative luciferase activities were presented as fold in-
duction to that of the vehicle control. The values are means
þ S.E.M. of 3^4 tests. *P6 0.05 compared with vehicle controls.
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level compared with that of the vehicle control (Fig. 5B). On
the other hand, the expression level of ECH was not in£u-
enced by the addition of any compounds. These data show
that isoprenols can regulate the expression of promoters of
PPARK target genes in human PPARK-transfected HepG2
hepatocytes.
4. Discussion
Nuclear receptors including PPARs require regulatory pro-
teins such as coactivators for their activation [31,32]. It is
possible to consider that the amount of coactivators in cells
could be a limiting factor in de¢ning the activity of nuclear
receptors. In particular, when a transient overexpression sys-
tem of nuclear receptors was used, the expression level of
coactivators could be one of the rate-limiting factors. There-
fore, we thought that the amount of coactivators was insu⁄-
cient for maximizing the ligand-dependent activity of PPARs
in luciferase assays. In such a case, coexpression of coactiva-
tors could improve the sensitivity of luciferase assays. Indeed,
the coexpression of CBP, one of the major coactivators, in-
creased luciferase activity induced by T174 and oleic acid as
shown in Fig. 1. The e¡ect of coactivator coexpression de-
pended on the amount of pCMX-CBP, a CBP expression
vector (data not shown). It is consistent with reports of other
groups in which the activities of several nuclear receptors or
transcriptional factors depended on the amount of coactivator
proteins [31^33]. The increase in what of transfected CBP
expression vectors might result in the decrease in transfecting
e⁄ciency because CBP cDNA is very long (about 9k bp). Our
condition reported here was the most e¡ective as determined
by several experiments. Generally, activation of PPARs by
natural compounds is not as strong as that by synthetic com-
pounds such as thiazolidinediones or ¢brates [34,35]. There-
fore, it is valuable for the screening of natural compounds
that the coactivator coexpression system be used to improve
the sensitivity of luciferase reporter assays. It is thought that
coactivator coexpression allows easy detection and estimation
of moderate e¡ects of natural compounds on PPAR activation.
We have here shown that several isoprenols, which are
components of medicinal plants used for managing hyperlip-
idemia or diabetes mellitus, can activate both PPARQ and
PPARK. In luciferase assays using the GAL4 chimera system,
farnesol and geranylgeraniol were e¡ective activators for both
PPARQ and PPARK, whereas geraniol was weaker than the
two. This was con¢rmed by analysis using full-length PPARQ
and PPARK proteins. PPARQ activation in adipose tissues
improves insulin resistance [19,20,36] and PPARK activation
in the liver induces a decrease in circulating lipid levels [22,23].
These e¡ects are due to the regulation at the mRNA level of
target genes of PPARs. The addition of these isoprenols up-
regulated several PPAR target genes in 3T3-L1 and HepG2
cells. In 3T3-L1 cells, LPL was not induced by isoprenols.
This might be because the e¡ect of isoprenols on gene induc-
tion was not so strong or di¡erent from that of synthetic
compounds due to the di¡erence in ligand type-speci¢c inter-
actions with coactivators [37]. However, isoprenols can regu-
late an adipocyte-speci¢c gene, aP2, which is regulated by
PPARQ in 3T3-L1 cells. aP2 was found to be central to the
pathway linking obesity to insulin resistance in a study using
aP2 mutant (3/3) mice [38]. Therefore, it is possible that
isoprenols could regulate insulin resistance and/or circulating
lipid levels. The ¢nding of the dual or cross-e¡ect of isopre-
nols in the activation of both PPARQ and PPARK is very
important in terms of clarifying the mechanisms by which
herbal plants exert their e¡ects and is valuable for managing
diabetes and hyperlipidemia using herbal medicine. Moreover,
this induction of PPAR target genes suggests that isoprenols
at appropriate concentrations could be e¡ective even in vivo.
Fig. 5. Farnesol and geranylgeraniol induced PPAR target genes in
3T3-L1 and HepG2 cells. A: E¡ects of isoprenols on di¡erentiated
3T3-L1 adipocytes. Di¡erentiated 3T3-L1 adipocytes were treated
with vehicle control (DMSO), 0.5 WM T174 (thiazolidinedione), 50
WM farnesol, and 50 WM geranylgeraniol for 24 h 7 days after the
di¡erentiation induction. Expression of mRNAs was estimated by
using LightCycler, a quantitative real-time RT-PCR (see Section 2).
B: E¡ects of isoprenols on HepG2 hepatocytes. HepG2 cells were
transfected with pDEST-hPPARK and treated with vehicle control
(DMSO), 20 WM feno¢brate, 100 WM farnesol, and 100 WM geranyl-
geraniol, respectively, 24 h after transfection. Total RNAs were pre-
pared 48 h after the addition of compounds. Expression level of a
vehicle control in each experiments was set at 100% and the relative
expression levels were presented as fold induction to that of the ve-
hicle control. All values are means þ S.E.M. of 5^6 tests. *P6 0.05
compared with vehicle controls.
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Indeed, farnesol and geraniol were e¡ective in suppressing
tumor growth in vitro at 50 and 150 WM IC50s, respectively
[39], which are similar to ED50s obtained in our luciferase
assays. Almost the same e¡ects were observed in rats fed
with diets containing 0.5^2.0% farnesol or geraniol [3^5,37].
Therefore, it is thought that isoprenols regulate the expression
of PPAR target genes in vivo as well as in vitro.
Furthermore, it is noteworthy that pyrophosphate forms of
farnesol and geranylgeraniol are intermediates in cholesterol
de novo synthesis from mevalonate. Interestingly, a recent
study showed that lavastatin, which is one of the inhibitors
of a rate-limiting enzyme, HMG-CoA reductase, in cholester-
ol de novo synthesis, downregulated glucose transporter 4
(Glut4) expression and suppressed glucose uptake into 3T3-
L1 cells to induce insulin resistance [40]. This suggests that
cholesterol de novo synthesis from mevalonate, which is
stimulated under the condition of cholesterol starvation, reg-
ulates Glut4 expression in 3T3-L1 cells. Moreover, Spiegelman
et al. reported that the overexpression of steroid-response el-
ement-binding proteins (SREBPs) in 3T3-L1 generated li-
gands that activated PPARQ [41]. This suggested that PPARQ
ligands were generated in cholesterol de novo synthesis, be-
cause SREBPs were activated under the condition of choles-
terol starvation and promoted cholesterol synthesis. Although
further studies are needed, it is possible that pyrophosphate
and/or pyrophosphate-free forms of farnesol and/or geranyl-
geraniol stimulate PPARQ to regulate the expression of Glut4
at the basal level or under the condition of cholesterol starva-
tion in 3T3-L1 cells.
Our previous study demonstrated that carotenoids and ret-
inoids regulated adipogenesis by changing PPARQ activity
[42]. In this study, we showed that isoprenols were also acti-
vators of PPARK and PPARQ, which controlled lipid metab-
olism. Therefore, it is thought that some phytochemicals,
which include carotenoids, terpenoids and isoprenoids, are
possible activators of PPARs. Our ¢ndings reported here pro-
vide not only a signi¢cant molecular basis of how herbal
medicines containing phytochemicals such as isoprenols im-
prove diabetes or hyperlipidemia, but also suggest the possi-
bility that phytochemicals have therapeutic applications in
lipid abnormalities, such as obesity, diabetes mellitus and hy-
perlipidemia.
Acknowledgements: This work was supported for a large part by a
grant-in-aid for Scienti¢c Research from the Ministry of Education,
Culture, Sports, Science and Technology of Japan (13460058), and
PROBRAIN Project from Bio-oriented Technology Research Ad-
vancement Institution, Japan.
References
[1] Elson, C.E., Underbakke, G.L., Hanson, P., Shrago, E., Wain-
berg, R.H. and Qureshi, A.A. (1989) Lipids 24, 677^679.
[2] Miller, A.L. (1998) Altern. Med. Rev. 3, 422^431.
[3] He, L., Mo, H., Hadisuslio, S., Qureshi, A.A. and Elson, C.E.
(1997) J. Nutr. 127, 668^674.
[4] Burke, Y.D., Stark, M.J., Roach, S.L., Sen, S.E. and Crowell,
P.L. (1997) Lipids 32, 151^156.
[5] Yu, S.G., Hildebrandt, L.A. and Elson, C.E. (1995) J. Nutr. 125,
2763^2767.
[6] Mo, H. and Elson, C.E. (1999) J. Nutr. 129, 804^813.
[7] Roullet, J.B., Luft, U.C., Xue, H., Champan, J., Bychkov, R.,
Roullet, C.M., Luft, F.C., Haller, H. and McCarron, D.A. (1997)
J. Biol. Chem. 272, 32240^32246.
[8] Bradfute, D.L. and Simoni, R.D. (1994) J. Biol. Chem. 269,
6645^6650.
[9] Correll, C.C., Ng, L. and Edwards, P.A. (1994) J. Biol. Chem.
269, 17390^17393.
[10] Kersten, S., Desvergne, B. and Wahli, W. (2000) Nature 405,
421^424.
[11] Braissant, O. and Wahli, W. (1998) Endocrinology 139, 2748^
2754.
[12] He, T.C., Chan, T.A., Vogelstein, B. and Kinzler, K.W. (1999)
Cell 99, 335^345.
[13] Hansen, J.B., Zhang, H., Rasmussen, T.H., Petersen, R.K.,
Flindt, E.N. and Kristiansen, K. (2001) J. Biol. Chem. 276,
3175^3182.
[14] Tontonoz, P., Hu, E. and Spiegelman, B.M. (1994) Cell 79, 1147^
1156.
[15] Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. and Spiegel-
man, B.M. (1994) Genes Dev. 8, 1224^1234.
[16] Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano,
P., Chien, K.R., Koder, A. and Evans, R.M. (1999) Mol. Cell 4,
585^595.
[17] Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K.,
Milstone, D.S., Spiegelman, B.M. and Mortensen, R.M. (1999)
Mol. Cell 4, 611^617.
[18] Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi,
T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T.,
Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara,
H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shio-
ta, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Nagai, R.,
Tobe, K., Kimura, S. and Kadowaki, T. (1999) Mol. Cell 4, 597^
609.
[19] Lehman, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O.,
Willson, T.M. and Kliewer, S.A. (1995) J. Biol. Chem. 270,
12953^12956.
[20] Willson, T.M., Cobb, J.E., Cowan, D.J., Wiethe, R.W., Correa,
I.D., Prakash, S.R., Beck, K.D., Moore, L.B., Kliewer, S.A. and
Lehnmann, J.M. (1996) J. Med. Chem. 39, 665^668.
[21] Hsu, M.H., Savas, U., Gri⁄n, K.J. and Johnson, E.F. (2001)
J. Biol. Chem. 276, 27950^27958.
[22] Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leiters-
dorf, E. and Fruchart, J.C. (1998) Circulation 98, 2088^2093.
[23] Peters, J.M., Hennuyer, N., Staels, B., Fruchart, J.C., Fievet, C.,
Gonzalez, F.J. and Auwerx, J. (1997) J. Biol. Chem. 272, 27307^
27312.
[24] Mizukami, J. and Taniguchi, T. (1997) Biochem. Biophys. Res.
Commun. 240, 61^64.
[25] Kawada, T., Kamei, Y. and Sugimoto, E. (1996) Int. J. Obes.
Relat. Metab. Disord. 20, S52^S57.
[26] Rasmussen, R. (2001) in: Quanti¢cation on the LightCycler (Me-
uer, S., Wittwer, C. and Nakagawara, K., Eds.), Rapid Cycle
Real-time PCR, pp. 21^34, Springer, Berlin.
[27] Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blan-
chard, S.G., Brown, P.J., Sternbach, D.D., Lehmann, J.M.,
Wisely, G.B., Willson, T.M., Kliewer, S.A. and Milburn, M.V.
(1999) Mol. Cell 3, 397^403.
[28] Simizu, S. and Yamada, H. (1985) in: Colorimetric Method
(Bergmeyer, H.U., Bergmeyer, J. and Grabl, M., Eds.), Methods
of Enzymatic Analysis, Vol. VIII, Metabolites 3, pp. 19^25, VCH
Verlagsgesellschaft, Weinheim.
[29] Dowell, P., Ishmael, J.E., Avram, D., Peterson, V.J., Nevrivy,
D.J. and Leid, M. (1997) J. Biol. Chem. 272, 33435^33443.
[30] Hida, Y., Kawada, T., Kayahashi, S., Ishihara, T. and Fushiki,
T. (1998) Life Sci. 62, 205^211.
[31] Gelman, L., Zhou, G., Fajas, L., Raspe, E., Fruchart, J.C. and
Auwerx, J. (1999) J. Biol. Chem. 274, 7681^7688.
[32] Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R.,
Gloss, B., Lin, S.C., Heyman, R.A., Rose, D.W., Glass, C.K.
and Rosenfeld, M.G. (1996) Cell 85, 403^414.
[33] Takemaru, K.I. and Moon, R.T. (2000) J. Cell Biol. 149, 249^
254.
[34] Forman, B.M., Chen, J. and Evans, R.M. (1997) Proc. Natl.
Acad. Sci. USA 94, 4312^4317.
[35] Ferry, G., Bruneau, V., Beauverger, P., Goussard, M., Rodri-
guez, M., Lamamy, V., Dromaint, S., Canet, E., Galizzi, J.P.
and Boutin, J.A. (2001) Eur. J. Pharmacol. 417, 77^89.
FEBS 25863 28-3-02
N. Takahashi et al./FEBS Letters 514 (2002) 315^322 321
[36] Willson, T.M., Lambert, M.H. and Kliewer, S.A. (2001) Annu.
Rev. Biochem. 70, 341^367.
[37] Kodera, Y., Takeyama, K., Murayama, A., Suzawa, M., Masu-
hiro, Y. and Kato, S. (2000) J. Biol. Chem. 275, 33201^33204.
[38] Hotamisligil, G.S., Johnson, R.S., Distel, R.J., Ellis, R., Pa-
paioannou, V.E. and Spiegelman, B.M. (1996) Science 274,
1377^1379.
[39] Elson, C.E. (1995) J. Nutr. 125, 1666S^1672S.
[40] Chamberlain, L.H. (2001) FEBS Lett. 507, 357^361.
[41] Kim, J.B., Wright, H.M., Wright, M. and Spiegelman, B.M.
(1998) Proc. Natl. Acad. Sci. USA 95, 4333^4337.
[42] Kawada, T., Kamei, Y., Fujita, A., Hida, Y., Takahashi, N.,
Sugimoto, E. and Fushiki, T. (2000) BioFactors 13, 103^109.
FEBS 25863 28-3-02
N. Takahashi et al./FEBS Letters 514 (2002) 315^322322
